AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34921514 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 1 μg/kg weekly for 2 weeks
Number of subjects: 16
Study 34921514 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim 3 μg/kg weekly for 2 weeks
Number of subjects: 16
Study 34921665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibegron
Number of subjects: 0
Study 34921665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34921668 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported cognitive interviewing using telephone and videoconferencing
Number of subjects: 0
Study 34921669 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (RISA) only
Number of subjects: 2101
Study 34921669 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Risankizumab (PBO/RISA)
Number of subjects: 2101
Study 34921669 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (UST) only
Number of subjects: 2101
Study 34921669 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) followed by re-randomization to ADA or RISA (ADA and ADA/RISA)
Number of subjects: 2101
Study 34921669 — intervention group
Group type: COMPARATOR
Intervention: Risankizumab followed by re-randomization to Risankizumab or placebo (RISA and RISA/PBO)
Number of subjects: 2101
Study 34921845 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (added in vitro)
Number of subjects: 21
Study 34921845 — intervention group
Group type: COMPARATOR
Intervention: PBMCs of IC patients
Number of subjects: 21
Study 34921845 — intervention group
Group type: COMPARATOR
Intervention: PBMCs of controls (healthy and cancer patients)
Number of subjects: 21
Study 34922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched products
Number of subjects: 7223
Study 34922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle measures to lower cholesterol
Number of subjects: 7223
Study 34922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 7223
Study 34922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing dietary fat
Number of subjects: 7223
Study 34922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 7223
Study 34922392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturative stress (measured using a 9-item scale)
Number of subjects: 400
Study 34922530 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Survivorship Care Index (PC-SCI)
Number of subjects: 1278
Study 34922610 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position ventilation
Number of subjects: 68
Study 34922610 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 68
Study 34922608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention delivered by trained community health workers over 12 months (5 one-on-one sessions, 4 group sessions, 13 telephone sessions).
Number of subjects: 3600
Study 34922608 — intervention group
Group type: COMPARATOR
Intervention: Usual care comprising a single 30-min session of lifestyle modification advice from the community health worker.
Number of subjects: 3600
Study 34922614 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS-based, drug resistance genotype-informed ART switching algorithm
Number of subjects: 152
Study 34922614 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up VL testing
Number of subjects: 152
Study 34922614 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic testing
Number of subjects: 152
Study 34922616 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartFeeding4Kids (SF4K) program, an online self-guided 7-session intervention for parents
Number of subjects: 0
Study 34922616 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34922648 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34922860 — intervention group
Group type: EXPERIMENTAL
Intervention: Active AL amyloidosis
Number of subjects: 69
Study 34922860 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission AL amyloidosis
Number of subjects: 69
Study 34922860 — intervention group
Group type: COMPARATOR
Intervention: Comparison of myocardial ECV between active and remission groups
Number of subjects: 69
Study 34922871 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter intervention for severe aortic stenosis
Number of subjects: 0
Study 34923853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous CD34+ cell therapy
Number of subjects: 20
Study 34923905 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 50
Study 34923905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34923911 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain inulin+resistant starch (INU+RS)
Number of subjects: 0
Study 34923911 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta glucan+resistant starch (BG+RS)
Number of subjects: 0
Study 34923911 — intervention group
Group type: COMPARATOR
Intervention: Beta glucan (BG)
Number of subjects: 0
Study 34923911 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (PLA)
Number of subjects: 0
Study 34924020 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 90
Study 34924020 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (Ringer's lactate)
Number of subjects: 90
Study 34924031 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI
Number of subjects: 25
Study 34924031 — intervention group
Group type: COMPARATOR
Intervention: IVIM-DWI
Number of subjects: 25
Study 34924034 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based patient education delivered through an e-learning programme at home
Number of subjects: 200
Study 34924034 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face patient education provided at the hospital
Number of subjects: 200
Study 34924145 — intervention group
Group type: EXPERIMENTAL
Intervention: entrectinib
Number of subjects: 0
Study 34925094 — intervention group
Group type: EXPERIMENTAL
Intervention: NDBI program augmented with Video Feedback (VF)
Number of subjects: 0
Study 34925094 — intervention group
Group type: COMPARATOR
Intervention: Early Intervention (EI) NDBI program
Number of subjects: 0
Study 34925157 — intervention group
Group type: EXPERIMENTAL
Intervention: Online transdiagnostic intervention with self-enhancement strategies
Number of subjects: 0
Study 34925157 — intervention group
Group type: COMPARATOR
Intervention: Online transdiagnostic intervention without self-enhancement strategies (control)
Number of subjects: 0
Study 34925553 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP107 (oral paclitaxel) 200 mg/m²
Number of subjects: 36
Study 34925553 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 36
Study 34926296 — intervention group
Group type: EXPERIMENTAL
Intervention: Tcm self-transfusion combined with TACE treatment
Number of subjects: 48
Study 34926296 — intervention group
Group type: COMPARATOR
Intervention: TACE treatment alone (control group)
Number of subjects: 48
Study 34926300 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with endoscopic therapy
Number of subjects: 89
Study 34926300 — intervention group
Group type: COMPARATOR
Intervention: TACE only (control group)
Number of subjects: 89
Study 34926300 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prophylaxis
Number of subjects: 89
Study 34926300 — intervention group
Group type: COMPARATOR
Intervention: Secondary prophylaxis
Number of subjects: 89
Study 34926386 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatments
Number of subjects: 0
Study 34926496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyponatremia
Number of subjects: 0
Study 34926496 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation at admission
Number of subjects: 0
Study 34926573 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34926601 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection
Number of subjects: 0
Study 34926601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34926604 — intervention group
Group type: EXPERIMENTAL
Intervention: Disproportionate Mitral Regurgitation
Number of subjects: 0
Study 34926707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 160
Study 34926707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation
Number of subjects: 160
Study 34926839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Brain Irradiation (SBI) by LINAC with monoisocentric technique and non-coplanar arcs
Number of subjects: 100
Study 34926839 — intervention group
Group type: COMPARATOR
Intervention: Whole Brain Irradiation (WBI)
Number of subjects: 100
Study 34926839 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Brain Irradiation (SBI)
Number of subjects: 100
Study 34926859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 110-149 mg/dl
Number of subjects: 144
Study 34926859 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 150-180 mg/dl
Number of subjects: 144
Study 34927159 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interventions
Number of subjects: 0
Study 34927159 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34927165 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth physical therapy
Number of subjects: 0
Study 34927165 — intervention group
Group type: COMPARATOR
Intervention: In-person physical therapy
Number of subjects: 0
Study 34927192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic measures
Number of subjects: 716
Study 34927192 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-pandemic measures
Number of subjects: 716
Study 34927192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had COVID-19
Number of subjects: 716
Study 34927307 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier locally ablative treatment of oligometastases
Number of subjects: 42
Study 34927477 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and physical intimate partner violence (IPV) from female partners to male partners
Number of subjects: 713
Study 34927477 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and physical intimate partner violence (IPV) from male partners to female partners
Number of subjects: 713
Study 34927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV)
Number of subjects: 0
Study 34927526 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 34927561 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 562
Study 34927561 — intervention group
Group type: COMPARATOR
Intervention: No-added iron
Number of subjects: 562
Study 34927594 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCENSO online platform (intervention group)
Number of subjects: 167
Study 34927594 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (control group)
Number of subjects: 167
Study 34927596 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention on diabetic retinopathy (DR) provided to health personnel using IEC materials (PowerPoint presentations, posters, pamphlets, videos, pre- and postevaluation questionnaires, referral slip).
Number of subjects: 0
Study 34927596 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention on diabetic retinopathy (DR).
Number of subjects: 0
Study 34928237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention using a neuroscience-based approach to mindfulness (Healthy Minds Program - HMP)
Number of subjects: 80
Study 34928237 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 34928249 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention for HPV vaccination (Development of Systems and Education for Human Papillomavirus Vaccination)
Number of subjects: 0
Study 34928316 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34928481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 62
Study 34928481 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 62
Study 34928491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 0
Study 34928709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 2 doses, followed by computed tomography scan at week 6.
Number of subjects: 60
Study 34928709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 3rd and 4th doses if no FATE at week 6, followed by Nivolumab monotherapy.
Number of subjects: 60
Study 34928709 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab + Ipilimumab (standard treatment)
Number of subjects: 60
Study 34928871 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care and sucrose for infant pain control
Number of subjects: 236
Study 34928871 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 236
Study 34929034 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 567
Study 34929034 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 567
Study 34929034 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with incident SARS-CoV-2 infection
Number of subjects: 567
Study 34930015 — intervention group
Group type: EXPERIMENTAL
Intervention: Melody transcatheter pulmonary valve (TPV) replacement
Number of subjects: 171
Study 34930020 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing for Mendelian arrhythmia genes
Number of subjects: 21846
Study 34930020 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of variant results
Number of subjects: 21846
Study 34930020 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro functional evaluation of 50 variants of uncertain significance
Number of subjects: 21846
Study 34930139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at 5 min after intubation (DS5)
Number of subjects: 50
Study 34930139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) from DS5 to OLV30
Number of subjects: 50
Study 34930139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at DS5, DL5, and OLV10
Number of subjects: 50
Study 34930139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORi) at DS5
Number of subjects: 50
Study 34930140 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 96 weeks
Number of subjects: 75
Study 34930140 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV) 0.5 mg once daily
Number of subjects: 75
Study 34930165 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1/BRCA2 somatic PSVs testing via next-generation sequencing (NGS)
Number of subjects: 105
Study 34930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Number of subjects: 105
Study 34930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Debulking surgery
Number of subjects: 105
Study 34930165 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline PSVs tests for patients with BRCA1/BRCA2 somatic PSVs
Number of subjects: 105
Study 34930172 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy for primary breast cancer
Number of subjects: 51
Study 34930182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Package (QIP) including a designated viral load champion, technological enhancement of TIER.Net, and a dashboard system.
Number of subjects: 750
Study 34930182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Package (QIP)
Number of subjects: 750
Study 34930182 — intervention group
Group type: COMPARATOR
Intervention: Current care (control)
Number of subjects: 750
Study 34930194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy + internet-delivered cognitive behavioral therapy (iCBT)
Number of subjects: 282
Study 34930194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy + iCBT in combination with TKA
Number of subjects: 282
Study 34930194 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment with TKA and usual care physiotherapy
Number of subjects: 282
Study 34930194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy + iCBT
Number of subjects: 282
Study 34930354 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 7
Study 34930354 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 7
Study 34930354 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 7
Study 34930354 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 7
Study 34930356 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum choline concentrations (median 9.51 μg/mL)
Number of subjects: 558
Study 34930356 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles 2-4 (serum choline ≥ 4.00 μg/mL)
Number of subjects: 558
Study 34930356 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drinking status
Number of subjects: 558
Study 34930356 — intervention group
Group type: COMPARATOR
Intervention: Low serum choline concentrations (median 7.80 μg/mL)
Number of subjects: 558
Study 34930368 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy
Number of subjects: 326
Study 34930368 — intervention group
Group type: COMPARATOR
Intervention: Intensity modulated photon radiation techniques (standard arm)
Number of subjects: 326
Study 34930401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB)
Number of subjects: 170
Study 34930401 — intervention group
Group type: COMPARATOR
Intervention: Plain balloon angioplasty (PBA)
Number of subjects: 170
Study 34930418 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-based BLS training
Number of subjects: 154
Study 34930418 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR training video
Number of subjects: 154
Study 34930421 — intervention group
Group type: EXPERIMENTAL
Intervention: 40Hz transcranial alternating current stimulation (tACS) administered 1 h daily for 2 or 4 weeks
Number of subjects: 15
Study 34930421 — intervention group
Group type: EXPERIMENTAL
Intervention: 40Hz transcranial alternating current stimulation (tACS)
Number of subjects: 15
Study 34930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic < 140 mmHg), glycemic control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤ 37.5 °C), reversal of anticoagulation (target INR < 1.5 within 1 hour)
Number of subjects: 8360
Study 34930428 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control phase)
Number of subjects: 8360
Study 34930440 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestion intervention by ICU doulas
Number of subjects: 43
Study 34930487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 141
Study 34930497 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator coaching style
Number of subjects: 137
Study 34930497 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal authority coaching style
Number of subjects: 137
Study 34930497 — intervention group
Group type: EXPERIMENTAL
Intervention: Delegator or personal model coaching styles
Number of subjects: 137
Study 34930500 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy including online training videos, customized algorithm, technology for workflow efficiency, implementation training, clinic support, coaching, and written protocols.
Number of subjects: 5
Study 34930717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild PVR
Number of subjects: 1128
Study 34930717 — intervention group
Group type: COMPARATOR
Intervention: None/Trace PVR
Number of subjects: 1128
Study 34930734 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery with additional treatment after bulla resection (specific details not provided).
Number of subjects: 450
Study 34930734 — intervention group
Group type: EXPERIMENTAL
Intervention: Various surgical options (specific details not provided).
Number of subjects: 450
Study 34930734 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse outcomes correlated with various treatments (specific details not provided).
Number of subjects: 450
Study 34930734 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of treatment methods (specific details not provided).
Number of subjects: 450
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion treatment at secondary hospitals
Number of subjects: 5063
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy at secondary hospitals
Number of subjects: 5063
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention at secondary hospitals
Number of subjects: 5063
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy timing
Number of subjects: 5063
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography timing
Number of subjects: 5063
Study 34930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset-to-first-medical-contact time at secondary hospitals
Number of subjects: 5063
Study 34930741 — intervention group
Group type: COMPARATOR
Intervention: Adjusted in-hospital mortality
Number of subjects: 5063
Study 34930741 — intervention group
Group type: COMPARATOR
Intervention: In-hospital death or treatment withdrawal
Number of subjects: 5063
Study 34930747 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress measured using the Clinical Outcomes in Routine Evaluation-Outcome Measure
Number of subjects: 0
Study 34930747 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by the EuroQol five-dimension-three-level
Number of subjects: 0